Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 25Recruiting 8Unknown 6Terminated 4Not yet recruiting 3Active not recruiting 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 31Small Cell Lung Carcinoma 13Triple Negative Breast Neoplasms 12Breast Neoplasms 9Ovarian Neoplasms 8Lung Neoplasms 7Endometrial Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Recurrence 3Neoplasms 3NSCLC 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Respiratory Tract Neoplasms 2Mouth Neoplasms 2Laryngeal Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma 2Brain Neoplasms 2Unresectable Locally Advanced or Metastatic Solid Tumors 1Thymoma 1Thymic epithelial tumor 1Thoracic Neoplasms 1Stomach Neoplasms 1Stage III and IV Ovarian Cancer 1Squamous Non-small Cell Lung Cancer 1Squamous NSCLC 1Solid Tumor Cancer 1Salivary Gland Malignant Neoplasms 1

Interventions

Cyclophosphamide 6fludarabine 5toripalimab 3Paclitaxel 3Etoposide 3Carboplatin 3Bevacizumab 3zimberelimab 2tislelizumab 2sintilimab 2glumetinib 2Vincristine 2Temozolomide 2Platinum 2Immune Checkpoint Inhibitors 2Hepatectomy 2Gemcitabine 2Drug Therapy 2Docetaxel 2Cisplatin 2Capecitabine 2venetoclax 1relmacabtagene autoleucel 1osimertinib 1lenvatinib 1irinotecan sucrosofate 1glofitamab 1gallium maltolate 1fludarabine phosphate 1eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Recurrence × Carboplatin × Clear all
NCT06751277 2024-12-27

QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer

Peking Union Medical College Hospital

Phase 2 Not yet recruiting
26 enrolled
Gynecologic

Recurrence, Endometrial Neoplasms

NCT05798819 2023-04-05

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Guangzhou Gloria Biosciences Co., Ltd.

Phase 3 Not yet recruiting
424 enrolled

Recurrence

NCT05715840 2023-02-08

Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3 Not yet recruiting
368 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡